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Abstract
Background:  Allergic subjects produce relatively low amounts of IFN-γ, a pleiotropic Th-1
cytokine that downregulates Th2-associated airway inflammation and hyperresponsiveness (AHR),
the hallmarks of allergic asthma. Adenovirus-mediated IFN-γ gene transfer reduces AHR, Th2
cytokine levels and lung inflammation in mice, but its use would be limited by the frequency of gene
delivery required; therefore, we tested chitosan/IFN-γ pDNA nanoparticles (CIN) for in situ
production of IFN-γ and its in vivo effects.
Methods: CIN were administered to OVA-sensitized mice to investigate the possibility of using
gene transfer to modulate ovalbumin (OVA)-induced inflammation and AHR.
Results: Mice treated with CIN exhibit significantly lower AHR to methacholine challenge and less
lung histopathology. Production of IFN-γ is increased after CIN treatment while the Th2-cytokines,
IL-4 and IL-5, and OVA-specific serum IgE are reduced compared to control mice. AHR and
eosinophilia are also significantly reduced by CIN therapy administered therapeutically in mice with
established asthma. CIN was found to inhibit epithelial inflammation within 6 hours of delivery by
inducing apoptosis of goblet cells. Experiments performed on STAT4-defective mice do not show
reduction in AHR with CIN treatment, thus implicating STAT4 signaling in the mechanism of CIN
action.
Conclusion:  These results demonstrate that mucosal CIN therapy can effectively reduce
established allergen-induced airway inflammation and AHR.
Introduction
Asthma is a chronic lung disease characterized by elevated
allergen-induced inflammation of the airway, typically
with infiltration of a number of inflammatory cells such
as eosinophils and epithelial hyperplasia leading to
hypersecretion of mucus. The chronic inflammation may
lead to structural alterations of the airway, airway remod-
eling and also to increased airway hyperresponsiveness
(AHR), the latter is usually reversible with treatment.
IFN-γ, a pleiotropic cytokine, promotes T-helper type-1
(Th1) responses, which downregulate the Th2-like
immune responses that are hallmarks of allergic diseases,
including asthma [1,2]. IFN-γ is considered to be a
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potential candidate for asthma therapy because of its
capacity to decrease: (i) IL-13-induced goblet cell hyper-
plasia and eosinophilia by upregulation of the IL-13Rα2
decoy receptor, which diminishes IL-13 signaling [3,4],
(ii) LTC4 production in murine and human macrophages
[5,6], human peripheral blood lymphocytes after wasp
venom immunotherapy [7], and in leukocytes of pollino-
sis patients [8], and (iii) TGF-β and procollagen-I and -III,
which cause fibrosis and airway remodeling [9,10].
Administration of recombinant IFN-γ reverses established
airway disease and inflammation in murine models
[11,12], but its use in treatment of asthma has been lim-
ited because of the short half-life of IFN-γ in vivo and the
potentially severe adverse effects associated with high
dose administration [13]. These drawbacks can be circum-
vented by the use of IFN-γ gene transfer which inhibits
both antigen- and Th2-induced pulmonary eosinophilia
and airway hyperreactivity [14,15]. The protective role of
plasmid DNA (pDNA)-encoded IFN-γ gene transfer in a
mouse model for respiratory syncytial virus infection[16]
and the role of IFN-γ as a genetic adjuvant in the immu-
notherapy of grass-allergic asthma [17] have previously
been reported. However, the pDNA-mediated gene trans-
fer for asthma has been hindered by the lack of an appro-
priate delivery system and also when performed under
physiologically permissible conditions, gene expression is
inefficient especially in non-dividing cells such as epithe-
lial cells.
An intranasal IFN-γ gene therapy approach for asthma
treatment was reported using adenovirus-mediated IFN-γ
gene transfer, which decreased AHR, Th2 cytokine levels
and lung inflammation [18]. This approach, also, is lim-
ited by the potentially acute inflammation of the airway
caused by the viral infection, and the frequency of gene
delivery required due to elimination of the virus by the
immune system. We therefore reasoned that a non-viral
intranasal IFN-γ gene delivery using chitosan nanoparti-
cles [19] may provide an effective approach for asthma
treatment. Chitosan, a natural, biocompatible cationic
polysaccharide prepared from crustacean shells, has
shown great potential as a vehicle for gene delivery [20–
25]. In this study, we examined the effects of chitosan-
IFN-γ pDNA nanoparticles (CIN) using a BALB/c mouse
model of allergic asthma. The results show that CIN ther-
apy significantly inhibits the production of IL-4, IL-5,
ovalbumin (OVA)-specific serum IgE, airway inflamma-
tion, and hyperreactivity. 
Materials and methods
Animals
Female 6 to 8 week-old wild type and STAT4-/- BALB/c
mice from Jackson Laboratory (Bar Harbor, ME) were
maintained in pathogen-free conditions at the University
of South Florida College of Medicine vivarium. All proce-
dures were reviewed and approved by the committees on
animal research at the University of South Florida College
of Medicine and VA Hospital.
Preparation of chitosan IFN-γ pDNA nanoparticles
IFN-γ cDNA was cloned in the mammalian expression
vector pVAX (Invitrogen, San Diego, CA), and complexed
with chitosan, as described before [19]. Briefly, recom-
binant plasmid dissolved in 25 mM Na2SO4 was heated
for 10 min at 55°C. Chitosan (Vanson, Redmond, WA)
was dissolved in 25 mM Na acetate, pH 5.4, to a final con-
centration of 0.02% and heated for 10 min at 55°C. After
heating, chitosan and DNA were mixed, vortexed vigor-
ously for 20–30 sec, and stored at room temperature until
use. Control mice were treated with chitosan nanoparti-
cles in the absence of DNA, with chitosan nanoparticles
complexed with empty vector, or with naked DNA alone.
Prevention of AHR
Mice were given 25 µg of chitosan-IFN-γ nanoparticles
intranasally (i.n.) per mouse on days 1, 2 and 3. Control
mice were given PBS, chitosan alone or IFN-γ plasmid
alone. On day 4, mice were allergen-sensitized by i.p.
injection of 50 µg of ovalbumin (OVA) adsorbed to 2 mg
of aluminum potassium sulfate (alum). On day 19, mice
were challenged intranasally with OVA (50 µg per
mouse). On day 22 following the last challenge, AHR to
methacholine was measured in conscious mice. On day
23, mice were bled and then sacrificed. Lungs and spleens
were removed and single-cell suspensions of splenocytes
were prepared and cultured in vitro in the presence of 100
µg/ml OVA or in medium alone.
Reversal of established AHR
Mice were sensitized i.p. with 50 µg OVA (adsorbed to
alum) on day 1 followed by intranasal challenge with 50
µg of OVA on day 14. On days 21–23, test mice were given
25  µg of chitosan-IFN-γ nanoparticles i.n. per mouse.
Control mice were given PBS, chitosan alone or IFN-γ
plasmid alone. Mice were further challenged i.n. with
OVA (50 µg/mouse) on days 27 through 29 and AHR was
measured on day 30. Mice were bled and sacrificed on day
31, and spleens and lungs removed.
Measurement of airway hyperresponsiveness
Airway hyperresponsiveness to inhaled methacholine was
measured in conscious mice using a whole body plethys-
mograph (Buxco, Troy, NY), as described before [26].
Results are expressed as mean enhanced pause (PENH) ±
SEM as percent of baseline (PBS only).
Examination of bronchoalveolar lavage (BAL) fluid
Mice were sacrificed and lungs were lavaged with 1 ml of
PBS introduced through the trachea. The BAL fluid wasGenetic Vaccines and Therapy 2003, 1 http://www.gvt-journal.com/content/1/1/3
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centrifuged 10 min at 300 × g, cells were rinsed with PBS
and resuspended. Aliquots of the cell suspension were
applied to slides using a cytospin apparatus (Shandon
Southern), stained and examined microscopically. Cells
were identified by morphological characteristics.
Splenocyte culture and assay for cytokines
Single-cell suspensions of splenocytes (3 × 105 cells/well
of a 24-well plate) were stimulated in vitro by incubation
with 100 µg/ml OVA. Supernatants were collected after 48
hours and ELISAs for IL-4, IL-5, and IFN-γ were done using
kits from R & D Systems (Minneapolis, MN).
OVA-specific IgE analysis
To determine the titer of OVA-specific IgE, a microtiter
plate was coated overnight at 4°C with 100 µl of OVA (5
mg/ml). Following three washes, nonspecific sites were
blocked with PBST (0.5% Tween-20 in PBS). Mouse sera
were added to the antigen-coated wells, the plates were
incubated, and bound IgE was detected with biotinylated
anti-mouse IgE (02112D; Pharmingen, CA). Biotin anti-
mouse IgE (02122D) reacts specifically with mouse IgE of
the Igha and Ighb haplotype and does not react with other
IgG isotypes. Streptavidin-peroxidase conjugate was
added and the bound enzyme was detected by addition of
the substrate tetramethylbenzidine and reading absorb-
ance at 450 nm.
Lung histology and apoptosis assay
Mice were sacrificed 24 hours after the last OVA challenge,
lungs were perfused in situ with PBS, removed, fixed in 4%
buffered formalin, paraffin-embedded and sectioned.
Lung inflammation was assessed by microscopic exami-
nation of sections stained with hematoxylin and eosin.
Unstained sections were examined for expression of the
goblet cell-specific marker Muc5a and for apoptosis by the
TUNEL (terminal deoxynucleotidyl transferase dUTP nick
end-labeling) assay method (DeadEndä Fluorometric
TUNEL Assay, Promega Corp., Madison, WI), as described
[27]. Briefly, lung sections were dewaxed in xylene, rehy-
drated, and fixed with 4% paraformaldehyde for 15 min.
Sections were then washed three times in PBS, perme-
ablized 15 min with 0.1 % Triton X-100, and incubated
one hour at 37°C with the TUNEL reagent. The reaction
was terminated by rinsing slides once with 2X SSC and
three times in PBS. Sections were then incubated with
antibody to Muc5a, washed and incubated with phyco-
erythrin-conjugated secondary antibody. The lung sec-
tions were observed microscopically and fluorescence
photographed using a Nikon TE300 fluorescence micro-
scope and digital camera. 
Statistical analysis
Values for all measurements are expressed as means ±
SEMs. Groups were compared by ANOVA and through the
use of paired Student's t tests. Differences between groups
were considered significant at p < 0.05.
Results
Expression of IFN-γ from CIN in lung
To determine the type of lung cells expressing the chi-
tosan-delivered genes, plasmid DNA expressing a green-
fluorescent protein (GFP) was administered intranasally
(i.n.) to mice. One day later, the lung sections from one
group of mice and the cells in BAL fluid from a parallel
group of mice were examined for GFP expression by fluo-
rescence microscopy. Lung sections showed that the GFP
was expressed principally by epithelial cells, while in BAL
fluid, monocytic cells expressed GFP (Fig. 1A). To exam-
ine the time course of gene expression, CIN or chitosan
alone was administered to groups of mice (n = 3) and the
level of expressed IFN-γ was determined by analysis of
lung homogenates from each group 1, 2, 4, 6, 8 or 10 days
after CIN administration. The results show that CIN rap-
idly induces IFN-γ expression and the level continues to
increase until day 4. However, by day 10 the IFN-γ in the
lung is back to the base level (Fig. 1B). Administration of
chitosan alone had little effect. These results show that
intranasal CIN administration promotes IFN-γ produc-
tion in the lung and that expression primarily occurs in
lung epithelial cells and monocytes.
Prophylactic administration of CIN attenuates allergen-
induced AHR and inflammation
IFN-γ promotes a Th1-like response to allergens. To deter-
mine whether prophylactic administration of CIN attenu-
ates sensitization to allergens, mice were first given CIN
therapy and then sensitized and challenged with OVA
(Fig. 2A). The effect of CIN therapy on airway hyperreac-
tivity was measured by whole body plethysmography.
CIN-treated mice showed a significantly (p < 0.01) atten-
uated AHR (% Penh) compared to non-treated mice or
mice given the IFN-γ plasmid alone as naked DNA (Fig.
2B). Furthermore, analysis of the cellular composition of
the BAL fluid from CIN-treated mice showed a doubling
of monocytes, while in the lungs there were significant
reductions in the numbers of eosinophils (Fig. 2C). Histo-
logical examination of lung sections (Fig. 2D) revealed
that CIN-treated mice exhibited a significant decrease in
epithelial denudation, mucus cell metaplasia, and cellular
infiltration compared to non-treated mice or mice given
naked IFN-γ plasmid.
Prophylactic administration of CIN attenuates 
sensitization to allergens
To determine whether the reduction in AHR in CIN-
treated mice was due to attenuated allergen sensitization,
Th2 cytokines were measured in splenocytes from the
three groups of mice. The CIN-treated mice showed signif-
icant reduction in the amount of IL-5 and IL-4 comparedGenetic Vaccines and Therapy 2003, 1 http://www.gvt-journal.com/content/1/1/3
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to control mice (Fig. 3A and 3B). In contrast, IFN-γ secre-
tion was significantly higher in CIN treated mice com-
pared to control mice (Fig. 3A). CIN-treated mice also
showed a significant reduction in IgE antibody levels
compared to the control group (Fig. 3C). These results
indicate that CIN prophylaxis results in the attenuation of
allergen sensitization.
Therapeutic administration of CIN reverses established 
allergen-induced AHR
Intranasal Ad-IFN-γ is capable of reversing established
AHR[28]. To determine whether therapeutic administra-
tion of CIN can attenuate established asthma, mice were
first sensitized and challenged with OVA and then given
CIN therapy, as shown in the protocol (Fig. 4A). Airway
hyperreactivity (%Penh) was measured by whole body
plethysmography (Fig. 4B) and CIN-treated mice again
had lower AHR than those mice given chitosan alone or
IFN-γ plasmid alone. The results show a complete reversal
to the basal level of AHR in the group of mice that were
treated with CIN. The number of eosinophils in the BAL
fluid showed a significant reduction in the CIN treated
mice (Fig. 4C) compared with the untreated control group
by staining the lung sections with antibody against
Muc5a, a marker that is specific for mucus-producing
cells. Furthermore, analysis of cytokine secretion from
splenocytes showed that there was an increase in IFN-γ
Chitosan nanoparticles target lung epithelial and monocytic cells Figure 1
Chitosan nanoparticles target lung epithelial and monocytic cells. (A) BALB/c mice were treated i.n. with chitosan 
nanoparticles containing pGFP. After 24 h, mice were sacrificed and their lungs were fixed and sectioned by cryotome. Sec-
tions (15 micron) were thaw-mounted to slides and viewed for green fluorescent protein ('Lung'). BAL cells were fixed after 
cytospin on a slide and visualized by fluorescence microscopy to identify GFP-expressing cells ('BAL'). (B) CIN administration 
induced IFN-γ production in the lung over a period of 10 days. Lung homogenates were prepared from mice after 1, 2, 4, 6, 8, 
or 10 days of treatment with CIN (25 µg/mouse) or chitosan alone, and IFN-γ levels were determined by ELISA (n = 3).
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production and a decrease in IL-4 and IL-5 production in
the CIN-treated mice compared to the controls (Fig. 4D).
Therapeutic administration of CIN reverses established 
allergen-induced inflammation by apoptosis of 
submucosal cells
To determine whether CIN therapy decreases established
pulmonary inflammation, lungs from OVA-sensitized
and OVA-challenged mice were examined 3, 6, 12 and 24
h after CIN administration. Histopathologic analysis of
the bronchial epithelium showed that mucosal cell hyper-
plasia began to attenuate after 6 h of CIN administration
(Fig. 5A, H&E). Staining of lung sections for apoptosis
(TUNEL assay) showed a significant number of TUNEL-
positive cells at 6 and 12 h after CIN administration,
which was back to normal by 24 h (Fig. 5B, TUNEL). In
Fig. 5C, the cells undergoing apoptosis (TUNEL) were
identified as goblet cells by staining the lung sections with
the mucus cell-specific marker, Muc5a. These results indi-
cate that CIN reverses epithelial inflammation rapidly
within hours.
CIN therapy involves the STAT4 signaling pathway
Ad-IFN-γ gene transfer, which produces significant
amounts of IFN-γ in the lung, has been shown to involve
the IL-12/ STAT4 signaling pathway [27]. To determine
Prevention of AHR Figure 2
Prevention of AHR. (A) Prophylaxis protocol. (B) Mice were challenged with methacholine on day 22 to measure airway 
responsiveness. The values are mean enhanced pause (PENH) expressed as percent of baseline ± SEM (* P < 0.05 and **P < 
0.01). (C) On day 24, BAL was performed and differential cell counts were obtained ('mac', macrophages; 'lym', lymphocytes; 
'neu', neutrophils; 'eos', eosinophils). (D) On day 24, lungs were removed, sectioned and the sections stained with hematoxy-
lin/eosin ('PBS', phosphate-buffered saline control; 'N-DNA', naked DNA without chitosan; 'CIN', chitosan-DNA complex). 
Differential cell counts and examination of tissue sections were performed by different persons in a blinded fashion. Represent-
ative results are shown.
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whether CIN also uses a STAT4 pathway, CIN therapy was
tested on STAT4-deficient mice (STAT4-/-). Wild type mice
showed the expected reduction in %Penh with CIN
treatment while the STAT4-deficient mice had no signifi-
cant change in AHR after CIN treatment (Fig. 6A). Lung
histopathology analysis of wild type and STAT4-/- mice
treated with CIN showed that CIN did not protect the
lungs of STAT4-/- mice (Fig. 6B) against inflammation.
These results suggest that STAT4 signaling is critical to the
effectiveness of CIN therapy.
Discussion
The role of IFN-γ in modulating allergen-induced asthma
has been described by many investigators, including our
laboratory [19,26,28]. Using mouse models, a variety of
approaches have been tried, ranging from i.p. administra-
tion of recombinant IFN-γ to adenovirus-mediated gene
transfer [11,12]. However, none of these approaches may
be suitable for utilizing IFN-γ therapy in humans. In this
report, a non-viral intranasal gene transfer strategy is
described using a human-friendly gene carrier, chitosan.
The results in a mouse model of allergic asthma demon-
strate that CIN therapy is potentially an effective
prophylactic and therapeutic treatment for asthma. Evi-
dence is also presented that, the immune modulation of
CIN therapy is STAT4 dependent.
Although chitosan has been previously administered
intranasally, the pattern of gene expression in the lung
mediated by plasmid DNA adsorbed to chitosan nanopar-
ticles has not been determined. The results of this study
show that the bronchial epithelium is the major target of
chitosan nanoparticles. In addition to epithelial cells,
macrophages appeared to also take up chitosan nanopar-
ticles. Both of these cell types play an important role in
asthma and in immunomodulation [29]. A major draw-
back of the adenovirus-mediated gene transfer is that
entry into bronchial epithelial cells requires the
Cocksackievirus and adenovirus receptor (CAR), which is
expressed on the basolateral, but not the apical, surface of
epithelial cells. Mucus may also interfere with adenoviral
gene transfer, whereas chitosan has been shown to have
muco-adhesive properties [30]. The role of monocytes is
important, as monocytes are activated in response to IFN-
γ production, which leads to IL-12 production and ampli-
fication of the IFN-γ cascade[31]. The time course of IFN-
γ expression through delivery of CIN is also distinct from
that of adenoviral-mediated IFN-γ expression in that the
amount of IFN-γ expression is only about two-fold higher
than the basal level, but the duration of IFN-γ production
is prolonged.
A significant finding was that treatment with CIN reversed
the course of asthma, as is evident from the normalization
of AHR and the return to normal lung morphology from
the hyper-inflammatory condition induced by OVA sensi-
tization and challenge. This result is consistent with our
previous observations and those of others. Furthermore,
the reduction in eosinophilia was greater with CIN ther-
apy than with Ad-IFN treatment. A novel finding is that
chitosan IFN-γ works within 3–6 h after intranasal admin-
CIN alters production of cytokines and IgE Figure 3
CIN alters production of cytokines and IgE. On day 23 
of the prophylactic procedure (see Fig. 2A) spleens were 
removed and single-cell suspensions of splenocytes were 
prepared. Cells were cultured for 48 h with OVA, and the 
levels of secreted IFN-γ and IL-5 (A) and IL-4 (B) were 
measured. Total serum IgE was measured on day 23 (C). Val-
ues are means ± SEM (*p < 0.05, **p < 0.01).
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istration, as mucus cell metaplasia was reduced as early as
6 h after treatment. This reduction is seen despite the fact
that CIN therapy produces about 10-fold less IFN-γ than
Ad-IFN-γ treatment. The effective transfection of lung epi-
thelial cells by CIN may account for this increased
effectiveness.
CIN therapy appears to induce IFN-γ gene expression pre-
dominantly in epithelial cells, and the reduction in AHR
and goblet cell hyperplasia may be due to IFN-γ directly or
may involve other Th1 cytokines such as IL-12. Two addi-
tional cytokines, IL-23 and TCCR (T cell cytokine recep-
tor), have been reported to exhibit IL-12-like effects in
that they also activate the transcription factor STAT4 [32–
34]. Therefore, to further verify the importance of the IL-
12 signaling pathway in mediating CIN effects, the role of
STAT4 was examined using STAT4-/- mice. No significant
difference in AHR was observed between OVA sensitized/
challenged STAT4-/- mice and OVA sensitized/challenged
and CIN-treated STAT4-/- mice. Also, epithelial damage
and inflammation in the lung was not attenuated in
STAT4-/- mice compared to the wild type control. These
results are in agreement with the findings that IL-4 levels
and Th2 cell numbers remain unchanged in asthmatics
with or without therapy[35]. Studies with ex vivo spleen
cells from STAT4-/-/STAT6-/- double-knockout mice dem-
Reversal of established AHR and eosinophilia Figure 4
Reversal of established AHR and eosinophilia. (A) Therapeutic protocol. (B) Mice were sensitized i.p. and challenged 
i.n. with OVA and treated with CIN as described. AHR was measured 24 h after the last challenge (n = 4). CIN-treated mice 
exhibited reduced AHR compared to the controls. Data are mean enhanced pause (PENH) expressed as percent of baseline ± 
SEM (*p < 0.05). (C) On day 31, BAL was performed and eosinophils in BAL fluid were counted (**p < 0.01). (D) On day 23, 
spleens were removed and single-cell suspensions of splenocytes prepared. Cells were cultured for 48 hours in the presence of 
OVA and cell supernatants were analyzed for IFN-γ, IL-4 and IL-5. Mice receiving CIN showed more IFN-γ and less IL-4 and IL-
5 compared to the chitosan-only control. Data are means ± SEM (*p < 0.05).
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onstrate the existence of a STAT4-independent pathway
for the development of Th1 cells [36]. Whether this occurs
in vivo is not yet known. T-bet, which promotes Th1 com-
mitment in an IL-12/STAT4-independent manner, is sup-
pressed by IL-4/STAT6, but induced by IFN-γ [37,38]. The
involvement of a STAT4-independent pathway in mediat-
ing CIN effects requires further investigation.
These results demonstrate that CIN therapy effectively
reduces the functional and immunological abnormalities
associated with allergen sensitization and challenge and
that this effect is predominantly mediated via a STAT4 sig-
naling pathway. Moreover, because of the similarities
between mice and humans in the T cell differentiation
pathway, these results indicate that CIN may be capable of
reversing allergic asthma in humans. These results are sig-
nificant given the limitations of therapy with recombinant
IFNs or adenovirus-mediated gene transfer, and CIN ther-
apy could be tailored to the needs of individuals who dif-
fer in their level of IFN-γ production and responsiveness.
In conclusion, intranasal CIN therapy may be useful for
both prophylaxis and treatment of asthma.
List of abbreviations
AHR, airway hyperresponsiveness; BAL, bronchoalveolar
lavage; CIN, chitosan interferon gamma nanoparticles;
OVA, ovalbumin; PENH, enhanced pause; STAT, signal
transducer and activator of transcription.
CIN treatment induces apoptosis of goblet cells Figure 5
CIN treatment induces apoptosis of goblet cells. BALB/c mice (n = 3) were sensitized and challenged with OVA as in 
Fig. 4 and then treated i.n. with CIN. Mice were sacrificed at 0, 3, 6, 12 and 24 h after CIN treatment and lungs were removed, 
sectioned and stained with hematoxylin/eosin (Fig. 5A), or unstained sections were analysed for apoptosis by TUNEL (terminal 
dUTP nick end labeling) assay (Fig. 5B). A final set of lung sections (Fig. 5C, 6 h time point) was stained for the goblet cell-spe-
cific protein Muc5a, and for apoptosis by the TUNEL assay. The first panel shows staining of nuclei with diamidinophenylindole 
(DAPI).
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